Shikiar Asset Management Inc. grew its holdings in shares of Allogene Therapeutics Inc (NASDAQ:ALLO) by 32.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 51,785 shares of the company’s stock after purchasing an additional 12,585 shares during the quarter. Shikiar Asset Management Inc.’s holdings in Allogene Therapeutics were worth $1,497,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in ALLO. Barclays PLC purchased a new stake in shares of Allogene Therapeutics during the fourth quarter worth approximately $27,000. Legal & General Group Plc acquired a new position in Allogene Therapeutics in the fourth quarter valued at approximately $89,000. Partner Investment Management L.P. acquired a new position in Allogene Therapeutics in the fourth quarter valued at approximately $135,000. Citigroup Inc. acquired a new position in Allogene Therapeutics in the fourth quarter valued at approximately $152,000. Finally, Strs Ohio acquired a new position in Allogene Therapeutics in the fourth quarter valued at approximately $156,000. 53.39% of the stock is currently owned by institutional investors.
NASDAQ:ALLO traded up $0.67 during trading hours on Friday, hitting $28.30. The company’s stock had a trading volume of 389,782 shares, compared to its average volume of 423,771. The stock has a market capitalization of $3.44 billion and a price-to-earnings ratio of -4.30. Allogene Therapeutics Inc has a 52-week low of $21.67 and a 52-week high of $35.55.
Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. Sell-side analysts anticipate that Allogene Therapeutics Inc will post -1.92 EPS for the current fiscal year.
A number of equities analysts recently issued reports on ALLO shares. Zacks Investment Research downgraded Allogene Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 28th. Cowen reissued a “buy” rating on shares of Allogene Therapeutics in a report on Friday, March 8th. JPMorgan Chase & Co. reissued a “hold” rating and issued a $29.00 price objective on shares of Allogene Therapeutics in a report on Monday, March 11th. William Blair started coverage on Allogene Therapeutics in a report on Wednesday, March 13th. They issued an “outperform” rating for the company. Finally, Raymond James started coverage on Allogene Therapeutics in a research note on Thursday, March 14th. They set an “outperform” rating and a $40.00 price target for the company. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Allogene Therapeutics has an average rating of “Buy” and a consensus target price of $36.63.
In other news, major shareholder Group Holdings (Sbs) Advis Tpg sold 1,918,755 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $29.38, for a total value of $56,373,021.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
ILLEGAL ACTIVITY NOTICE: “Shikiar Asset Management Inc. Boosts Stake in Allogene Therapeutics Inc (NASDAQ:ALLO)” was first published by Sundance Herald and is owned by of Sundance Herald. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://sundanceherald.com/2019/05/24/shikiar-asset-management-inc-has-1-50-million-position-in-allogene-therapeutics-inc-allo.html.
Allogene Therapeutics Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Featured Article: Call Option
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.